Deferiprone is the only orally active iron-chelating agent with an affinity for ferric ion (iron III)，binds with ferric ions to form neutral 3:1 (deferiprone:iron) complexes that are stable over a wide range of pH values. Deferiprone is used therapeutically in conditions of transfusional iron overload.
| Molecular Weight | 139.15 |
| Formula | C7H9NO2 |
| CAS Number | 30652-11-0 |
| Solubility (25°C) | DMSO 6 mg/mL Water 3 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
[2] Robert C Hider, et al. The Role of Deferiprone in Iron Chelation
[3] Ami Belmont, et al. Deferiprone for the treatment of transfusional iron overload in thalassemia
[4] Sheila A Fisher, et al. Oral deferiprone for iron chelation in people with thalassaemia
| Related Ferroptosis Products |
|---|
| PRDX3(103-112) SO3 modified, human
PRDX3(103-112) SO3 modified, human is a marker of ferroptosis, and can be used for liver diseases study. |
| PRDX3(103-112), human
PRDX3(103-112), human is a marker for ferroptosis. |
| GPX4-IN-3
GPX4-IN-3 is a potent glutathione peroxidase 4 (GPX4) inhibitor that selectively induces ferroptosis.1 μM of GPX4-IN-3 inhibited 71.7% of GPX4 activity. |
| YL-939
YL-939 is a potent ferroptosis inhibitor that inhibits iron death by targeting the PHB2/ferritin/iron axis. |
| MMRi62
MMRi62 is a ferroptosis inducer targeting MDM2-MDM4 (negative regulator of the oncogene p53), which induces ferroptosis accompanied by an increase in reactive oxygen species (ROS) and lysosomal degradation of ferritin heavy chain (FTH1).MMRi62 displays p53-independent apoptosis activity and induces autophagy in pancreatic ductal adenocarcinoma (PDAC) cells. MMRi62 shows p53-independent pro-apoptosis activity and induces autophagy in pancreatic ductal adenocarcinoma (PDAC) cells.) In addition, MMRi62 caused proteasomal degradation of mutant p53 and was active in vivo in an in situ xenograft PDAC mouse model characterized by high-frequency mutations in KRAS and TP53. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
